Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04035005




Registration number
NCT04035005
Ethics application status
Date submitted
17/07/2019
Date registered
29/07/2019
Date last updated
1/10/2024

Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Scientific title
A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Secondary ID [1] 0 0
WA40404
Universal Trial Number (UTN)
Trial acronym
O'HAND
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Sclerosis, Primary Progressive 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ocrelizumab
Treatment: Drugs - Placebo

Experimental: Ocrelizumab - Participants will receive ocrelizumab by IV infusion every 24 weeks.

Placebo comparator: Placebo - Participants will receive placebo matched to ocrelizumab by IV infusion every 24 weeks.


Treatment: Drugs: Ocrelizumab
The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg infusion every 24 weeks. A minimum interval of 20 or 22 weeks, depending if the previous dose was administered in one or two infusion, should be maintained between each infusion.

Treatment: Drugs: Placebo
The first dose of placebo will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, placebo will be administered as a single 600 mg infusion every 24 weeks, with a minimum interval of 20 or 22 weeks, depending if the previous dose was administered in one or two infusion, should be maintained between each infusion.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to Upper Limb Disability Progression Confirmed For at Least 12 Weeks
Timepoint [1] 0 0
Baseline up to approximately 5.5 years
Secondary outcome [1] 0 0
Time to Upper Limb Disability Progression Confirmed For at Least 24 Weeks
Timepoint [1] 0 0
Baseline up to approximately 5.5 years
Secondary outcome [2] 0 0
Time to Disability Progression Confirmed For at Least 12 Weeks
Timepoint [2] 0 0
Baseline up to approximately 5.5 years
Secondary outcome [3] 0 0
Time to Disability Progression Confirmed For at Least 24 Weeks
Timepoint [3] 0 0
Baseline up to approximately 5.5 years
Secondary outcome [4] 0 0
Percent Change in Total Volume of T2 Lesions on MRI
Timepoint [4] 0 0
Baseline up to week 120
Secondary outcome [5] 0 0
Percent Change in Total Brain Volume on MRI Scans
Timepoint [5] 0 0
Week 24 to Week 120
Secondary outcome [6] 0 0
Percentage of Participants with Adverse Events
Timepoint [6] 0 0
Baseline up to 8.5 years
Secondary outcome [7] 0 0
Percentage of Participants With Serious Adverse Events
Timepoint [7] 0 0
Baseline up to 8.5 years
Secondary outcome [8] 0 0
Area Under the Serum Concentration-Time Curve (AUC) of Ocrelizumab
Timepoint [8] 0 0
Baseline, Weeks 2, 12, 24, 48, 60, 72, and every 12 weeks till the end of the double-blind period and Weeks 0 and 48 of the OLE period
Secondary outcome [9] 0 0
Evaluation of Ocrelizumab Pharmacodynamics, as measured by B-Cell Levels in Blood
Timepoint [9] 0 0
Baseline, Weeks 2, 24, 48, 72 and every 12 weeks till the end of the double-blind period and Weeks 0, 22, 46, 70 and 96 of the OLE period

Eligibility
Key inclusion criteria
* EDSS score at screening and baseline >= 3.0 to 8.0, inclusive
* Disease duration from the onset of MS symptoms relative to randomization date:

Less than 20 years in patients with an EDSS score at screening 7.0 - 8.0 Less than 15 years in patients with an EDSS at screening 5.5 - 6.5 Less than 10 years in patients with an EDSS at screening <= 5.0

* Documented history or presence at screening of at least one of the following laboratory findings in a cerebrospinal fluid specimen: Elevated IgG index or one or more IgG oligoclonal bands detected by isoelectric focusing
* Screening and baseline 9-HPT completed in > 25 seconds (average of the two hands)
* Neurological stability for = 30 days prior to baseline
* Ability to complete the 9-HPT within 240 seconds with each hand at screening and baseline
* Neurological stability for >/= 30 days prior to baseline
* Patients previously treated with immunosuppressants, immunomodulators, or other immunomodulatory therapies must undergo an appropriate washout period according to the local label of the immunosuppressant/immunomodulatory drug used
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate contraceptive methods during the treatment period and for 6 or 12 months after the final dose of ocrelizumab. Adherence to local requirements, if more stringent, is required.
* For female patients without reproductive potential: Women may be enrolled if surgically sterile (i.e hysterectomy, complete bilateral oophorectomy) or post-menopausal unless the patient is receiving a hormonal therapy for her menopause or if surgically sterile
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* History of relapsing-remitting or secondary progressive MS at screening
* Confirmed serious opportunistic infection including: active bacterial, viral, fungal, mycobacterial infection or other infection, including tuberculosis or atypical mycobacterial disease
* Patients who have or have had confirmed or a high degree of suspicion of progressive multifocal leukoencephalopathy (PML)
* Known active malignancy or are being actively monitored for recurrence of malignancy
* Immunocompromised state
* Receipt of a live-attenuated vaccine within 6 weeks prior to randomization
* Inability to complete an MRI or contraindication to Gd administration.
* Patients requiring symptomatic treatment of MS and/or physiotherapy who are not on a stable regimen. Patients must not initiate symptomatic treatment of MS or physiotherapy within 4 weeks of randomization.
* Contraindications to mandatory premedications for infusion-related reactions, including:

uncontrolled psychosis for corticosteroids and closed-angle glaucoma for antihistamines

* Known presence of other neurologic disorders
* Pregnant or breastfeeding, or intending to become pregnant during the study and for 6 or 12 months after last infusion of the study drug
* Lack of peripheral venous access
* Significant, uncontrolled disease, such as cardiovascular, pulmonary, renal, hepatic, endocrine or gastrointestinal, or any other significant disease that may preclude patient from participating in the study
* Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
* History of alcohol or other drug abuse
* History of primary or secondary immunodeficiency
* Treatment with any investigational agent within 24 weeks prior to screening (Visit 1) or 5 half-lives of the investigational drug (whichever is longer), or treatment with any experimental procedure for MS
* Previous treatment with B-cell targeting therapies
* Any previous treatment with bone marrow transplantation and hematopoietic stem cell transplantation
* Any previous history of transplantation or anti-rejection therapy
* Treatment with IV Ig or plasmapheresis within 12 weeks prior to randomization
* Systemic corticosteroid therapy within 4 weeks prior to screening
* Positive serum hCG measured at screening or positive urine ß-hCG at baseline
* Positive screening tests for hepatitis B
* Any additional exclusionary criterion as per ocrelizumab (Ocrevus®) local label, if more stringent than the above
* Lack of MRI activity at screening/baseline if more than 650 patients without MRI activity have already been enrolled, as defined by T1 Gd+ lesion(s) and/or new and/or enlarged T2 lesion(s) in the screening, to ensure that at least 350 patients with MRI activity will be randomized

Eligibility Criteria for Open-Label Extension Phase:

* Completed the double-blind treatment phase of the trial or have received PDP OCR in the FU1 phase, and who, in the opinion of the investigator, may benefit from treatment with Ocrelizumab. Patients who withdrew from study treatment and received another disease-modifying therapy (DMT) or commercial ocrelizumab will not be allowed to enter in the OLE phase.
* Meet the re-treatment criteria for ocrelizumab
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate contraceptive methods during the treatment period and for 6 or 12 months after the final dose of ocrelizumab. Adherence to local requirements, if more stringent, is required.
* For female patients without reproductive potential: Women may be enrolled if surgically sterile (i.e. hysterectomy, complete bilateral oophorectomy) or post-menopausal unless the patient is receiving a hormonal therapy for her menopause or if surgically sterile

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/08/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
19/01/2028
Actual
Sample size
Target
1000
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Brain and Mind Research Institute - Camperdown
Recruitment hospital [2] 0 0
John Hunter Hospital - New Lambton
Recruitment hospital [3] 0 0
Austin Hospital - Heidelberg
Recruitment hospital [4] 0 0
Royal Melbourne Hospital - Parkville
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2305 - New Lambton
Recruitment postcode(s) [3] 0 0
3084 - Heidelberg
Recruitment postcode(s) [4] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Nebraska
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Virginia
Country [14] 0 0
United States of America
State/province [14] 0 0
Wisconsin
Country [15] 0 0
Austria
State/province [15] 0 0
Linz
Country [16] 0 0
Belgium
State/province [16] 0 0
Bruxelles
Country [17] 0 0
Belgium
State/province [17] 0 0
Edegem
Country [18] 0 0
Belgium
State/province [18] 0 0
La Louvière
Country [19] 0 0
Belgium
State/province [19] 0 0
Overpelt
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Pleven
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Sofia
Country [22] 0 0
Canada
State/province [22] 0 0
Alberta
Country [23] 0 0
Canada
State/province [23] 0 0
Nova Scotia
Country [24] 0 0
Canada
State/province [24] 0 0
Ontario
Country [25] 0 0
Canada
State/province [25] 0 0
Quebec
Country [26] 0 0
Colombia
State/province [26] 0 0
Bogota, D.C.
Country [27] 0 0
Colombia
State/province [27] 0 0
Medellin
Country [28] 0 0
Croatia
State/province [28] 0 0
Osijek
Country [29] 0 0
Croatia
State/province [29] 0 0
Varazdin
Country [30] 0 0
Croatia
State/province [30] 0 0
Zagreb
Country [31] 0 0
Egypt
State/province [31] 0 0
Cairo
Country [32] 0 0
France
State/province [32] 0 0
Amiens Cedex1
Country [33] 0 0
France
State/province [33] 0 0
Bordeaux
Country [34] 0 0
France
State/province [34] 0 0
Cedex
Country [35] 0 0
France
State/province [35] 0 0
Clermont-ferrand
Country [36] 0 0
France
State/province [36] 0 0
Colmar
Country [37] 0 0
France
State/province [37] 0 0
Marseille
Country [38] 0 0
France
State/province [38] 0 0
Montpellier
Country [39] 0 0
France
State/province [39] 0 0
Nancy
Country [40] 0 0
France
State/province [40] 0 0
Nantes
Country [41] 0 0
France
State/province [41] 0 0
Nimes
Country [42] 0 0
France
State/province [42] 0 0
Strasbourg
Country [43] 0 0
Georgia
State/province [43] 0 0
Tbilisi
Country [44] 0 0
Germany
State/province [44] 0 0
Hannover
Country [45] 0 0
Hungary
State/province [45] 0 0
Kecskemet
Country [46] 0 0
Hungary
State/province [46] 0 0
Tatabánya
Country [47] 0 0
Ireland
State/province [47] 0 0
Dublin
Country [48] 0 0
Italy
State/province [48] 0 0
Campania
Country [49] 0 0
Italy
State/province [49] 0 0
Lazio
Country [50] 0 0
Italy
State/province [50] 0 0
Liguria
Country [51] 0 0
Italy
State/province [51] 0 0
Lombardia
Country [52] 0 0
Italy
State/province [52] 0 0
Piemonte
Country [53] 0 0
Italy
State/province [53] 0 0
Sicilia
Country [54] 0 0
Lebanon
State/province [54] 0 0
Achrafieh
Country [55] 0 0
Lebanon
State/province [55] 0 0
Beirut
Country [56] 0 0
Mexico
State/province [56] 0 0
Mexico CITY (federal District)
Country [57] 0 0
Mexico
State/province [57] 0 0
Sinaloa
Country [58] 0 0
Mexico
State/province [58] 0 0
Chihuahua
Country [59] 0 0
Mexico
State/province [59] 0 0
Durango
Country [60] 0 0
Mexico
State/province [60] 0 0
Monterrey
Country [61] 0 0
Morocco
State/province [61] 0 0
Marrakech
Country [62] 0 0
Morocco
State/province [62] 0 0
Rabat
Country [63] 0 0
New Zealand
State/province [63] 0 0
Christchurch
Country [64] 0 0
New Zealand
State/province [64] 0 0
Dunedin
Country [65] 0 0
New Zealand
State/province [65] 0 0
Hamilton
Country [66] 0 0
New Zealand
State/province [66] 0 0
Wellington
Country [67] 0 0
Poland
State/province [67] 0 0
Bia?ystok
Country [68] 0 0
Poland
State/province [68] 0 0
Bydgoszcz
Country [69] 0 0
Poland
State/province [69] 0 0
Gdansk
Country [70] 0 0
Poland
State/province [70] 0 0
Grodzisk Mazowiecki
Country [71] 0 0
Poland
State/province [71] 0 0
Katowice
Country [72] 0 0
Poland
State/province [72] 0 0
Kielce
Country [73] 0 0
Poland
State/province [73] 0 0
Kraków
Country [74] 0 0
Poland
State/province [74] 0 0
Lodz
Country [75] 0 0
Poland
State/province [75] 0 0
Lublin
Country [76] 0 0
Poland
State/province [76] 0 0
Olsztyn
Country [77] 0 0
Poland
State/province [77] 0 0
Pozna?
Country [78] 0 0
Poland
State/province [78] 0 0
Poznan
Country [79] 0 0
Poland
State/province [79] 0 0
Rybnik
Country [80] 0 0
Poland
State/province [80] 0 0
Rzeszow
Country [81] 0 0
Poland
State/province [81] 0 0
Szczecin
Country [82] 0 0
Poland
State/province [82] 0 0
Warsaw
Country [83] 0 0
Poland
State/province [83] 0 0
Warszawa
Country [84] 0 0
Portugal
State/province [84] 0 0
Almada
Country [85] 0 0
Portugal
State/province [85] 0 0
Braga
Country [86] 0 0
Portugal
State/province [86] 0 0
Loures
Country [87] 0 0
Portugal
State/province [87] 0 0
Porto
Country [88] 0 0
Portugal
State/province [88] 0 0
Torres Vedras
Country [89] 0 0
Romania
State/province [89] 0 0
Bucharest
Country [90] 0 0
Romania
State/province [90] 0 0
Campulung
Country [91] 0 0
Romania
State/province [91] 0 0
Caracal
Country [92] 0 0
Romania
State/province [92] 0 0
Constan?a
Country [93] 0 0
Romania
State/province [93] 0 0
Hunedoara
Country [94] 0 0
Romania
State/province [94] 0 0
Targu Mures
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Altaj
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Baskortostan
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Krasnojarsk
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Moskovskaja Oblast
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Niznij Novgorod
Country [100] 0 0
Russian Federation
State/province [100] 0 0
Sankt Petersburg
Country [101] 0 0
Russian Federation
State/province [101] 0 0
Saratov
Country [102] 0 0
Russian Federation
State/province [102] 0 0
Sverdlovsk
Country [103] 0 0
Russian Federation
State/province [103] 0 0
Tatarstan
Country [104] 0 0
Russian Federation
State/province [104] 0 0
Uljanovsk
Country [105] 0 0
Russian Federation
State/province [105] 0 0
Belgorod
Country [106] 0 0
Russian Federation
State/province [106] 0 0
Kemerovo
Country [107] 0 0
Russian Federation
State/province [107] 0 0
Kirov
Country [108] 0 0
Russian Federation
State/province [108] 0 0
Nizniy Novgorod
Country [109] 0 0
Russian Federation
State/province [109] 0 0
Novosibirsk
Country [110] 0 0
Russian Federation
State/province [110] 0 0
Perm
Country [111] 0 0
Russian Federation
State/province [111] 0 0
Tomsk
Country [112] 0 0
Russian Federation
State/province [112] 0 0
Tver
Country [113] 0 0
Serbia
State/province [113] 0 0
Belgrade
Country [114] 0 0
Serbia
State/province [114] 0 0
Kragujevac
Country [115] 0 0
Serbia
State/province [115] 0 0
NIS
Country [116] 0 0
Serbia
State/province [116] 0 0
Nova Sad
Country [117] 0 0
Serbia
State/province [117] 0 0
Uzice
Country [118] 0 0
Serbia
State/province [118] 0 0
Zemun
Country [119] 0 0
Spain
State/province [119] 0 0
Madrid
Country [120] 0 0
Spain
State/province [120] 0 0
Pontevedra
Country [121] 0 0
Spain
State/province [121] 0 0
Sevilla
Country [122] 0 0
Spain
State/province [122] 0 0
Vizcaya
Country [123] 0 0
Spain
State/province [123] 0 0
Barcelona
Country [124] 0 0
Spain
State/province [124] 0 0
Castellon
Country [125] 0 0
Spain
State/province [125] 0 0
Malaga
Country [126] 0 0
Spain
State/province [126] 0 0
Murcia
Country [127] 0 0
Spain
State/province [127] 0 0
Salamanca
Country [128] 0 0
Spain
State/province [128] 0 0
Valencia
Country [129] 0 0
Tunisia
State/province [129] 0 0
Mannouba
Country [130] 0 0
Tunisia
State/province [130] 0 0
Monastir
Country [131] 0 0
Tunisia
State/province [131] 0 0
Sfax
Country [132] 0 0
Tunisia
State/province [132] 0 0
Tunis
Country [133] 0 0
Ukraine
State/province [133] 0 0
Chernihiv Governorate
Country [134] 0 0
Ukraine
State/province [134] 0 0
Crimean Regional Governmenta
Country [135] 0 0
Ukraine
State/province [135] 0 0
Katerynoslav Governorate
Country [136] 0 0
Ukraine
State/province [136] 0 0
Kharkiv Governorate
Country [137] 0 0
Ukraine
State/province [137] 0 0
Kherson Governorate
Country [138] 0 0
Ukraine
State/province [138] 0 0
KIEV Governorate
Country [139] 0 0
Ukraine
State/province [139] 0 0
Podolia Governorate
Country [140] 0 0
Ukraine
State/province [140] 0 0
Polissya Okruha
Country [141] 0 0
Ukraine
State/province [141] 0 0
Tavria Okruha
Country [142] 0 0
Ukraine
State/province [142] 0 0
Volhynian Governorate
Country [143] 0 0
Ukraine
State/province [143] 0 0
Kyiv
Country [144] 0 0
Ukraine
State/province [144] 0 0
Lutsk
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Cardiff
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Glasgow
Country [147] 0 0
United Kingdom
State/province [147] 0 0
Inverness
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Liverpool
Country [149] 0 0
United Kingdom
State/province [149] 0 0
London
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Nottingham
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Plymouth
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Salford
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Sheffield
Country [154] 0 0
United Kingdom
State/province [154] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course. This study focuses on upper limit disability progression. This study will consist of the following phases: screening, double-blind treatment, follow-up 1 (FU1), an optional open-label extension (OLE), follow-up 2 (FU2), and B-cell monitoring (BCM).
Trial website
https://clinicaltrials.gov/study/NCT04035005
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Reference Study ID Number: WA40404 https://forpatients.roche.com/
Address 0 0
Country 0 0
Phone 0 0
888-662-6728 (U.S. and Canada)
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04035005